OPYT PRIMENENIYa NOVOY LEKARSTVENNOY FORMY PREPARATA TEMOZOLOMID: RASShIRYaYa VOZMOZhNOSTI LEChENIYa
- Authors: Naskhletashvili D.R1, Sharabura T.M1
-
Affiliations:
- Issue: No 8 (2013)
- Pages: 66-70
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/281223
- ID: 281223
Cite item
Open Access
Access granted
Abstract
Temozolomide is the most effective drug for the treatment of malignant gliomas. All patients included in the study and treated with temozolomide in both dosage forms have reported better tolerance of intravenous infusion in comparison with oral capsules. Advantages of intravenous infusion of the temozolomida best implemented in patients with impaired swallowing, as well as children. Limitations of use of lyophilisate include necessity for admission of patient in a medical facility. However, the low toxicity of intravenous infusion of temozolomide allowed to recommend administration of this drug in a day hospital or in outpatient settings. Thus, the presence of two formulations enhances the use of temozolomide in patients with malignant gliomas, allows to provide treatment with low toxicity and ensure the highest quality of life during treatment.
Full Text
References
- Diez B.D., Statkevich P., Zhu Y., et al. Evaluation of the exposure equivalence of oral versus intravenous temozolomide. Ottaviano Cancer Chemother Pharmacol 2010;65(4): 727-34.
- Motomura K., Natsume А., Wakabayashi Т. Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsulesin patients with gliomas. J Neurooncol (2012) 106:209-211.
- Patel M., McCully C., Godwin Ket al. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 2003;61(3):203-07.
- Reyderman L., Statkevich P., Thonoor C.M., et al. Disposition and pharmacokinetics of temozolomide in rat. Xenobiotica 2004;34 (5):487-500.
- Jen J.F., Cutler D.L., Pai S.M., et al. Population pharmacokinetics of temozolomide in cancer study: 5-year analysis of the EORTC-NCIC trial. The lancet oncology 2009;10(5):459-66.
- Stupp R., Mason W.P., van der Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352 (10):987-96.
- Gerson S.l. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20 (9):2388-99.
- Stupp R., Hegi M.E., Mirimanoff R.O., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in randomized phase III patients. Pharm Res 2000;17(10):1284-89.
Supplementary files
